Please login to the form below

Not currently logged in
Email:
Password:

Pfizer scraps RA drug

Pfizer has decided to scrap development of TRU-015 for the treatment of rheumatoid arthritis

Pfizer has decided to scrap development of a drug for a very large market – rheumatoid arthritis (RA). Seattle-based Trubion Pharmaceuticals, which has a collaboration in RA with the company, said that Pfizer has terminated development of TRU-015, a protein therapeutic product.

The decision is based on a phase IIb study which did not meet its primary endpoint of a 20 per cent reduction on an American College of Rheumatology disease scoring index compared to placebo.

Trubion noted that Pfizer intends to continue development of another RA product that is part of the collaboration, SBI-087. That drug is currently in a phase II study.

15th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics